Results 181 to 190 of about 29,631 (205)

Signatures of Trained Immunity Following mRNA Vaccination: Differences Between mRNA-1273 and BNT162b2. [PDF]

J Clin Immunol
Kunc M, Whitehead BJ, Østergaard LJ, Tolstrup M, Benn CS, Wejse CM, Nejsum P.   +6 more
europepmc   +1 more source

Association between nucleic acid COVID-19 vaccines and acute myocardial infarction in adults: a systematic review. [PDF]

Front Cardiovasc Med
Castellanos-Hernández DI, Mayoral-Chávez MA, Matias-Cervantes CA, Alpuche J.   +3 more
europepmc   +1 more source

Novel approach for vaccine delivery using mRNA lipid nanoparticles for <i>in vivo</i> production of monoclonal antibodies. [PDF]

Mol Ther Nucleic Acids
Lundstrom K.
europepmc   +1 more source

Effectiveness and Durability of the BNT162b2 KP.2 Vaccine Against COVID-19 Hospitalization and Emergency Department or Urgent Care Encounters in US Adults. [PDF]

Open Forum Infect Dis
Tartof SY, Frankland TB, Slezak JM, Ackerson BK, Puzniak L.   +4 more
europepmc   +1 more source

Myocarditis after COVID-19 mRNA vaccination in Norway: a nationwide validation study. [PDF]

Open Heart
Hagen BS, Vlaisavljevic K, Oppedal LS, Endresen J, Mohn VS, Fladseth K, Lysaker TM, Ribe MP, Möller TF, Hole TL, Dahl J, Karlstad Ø, Gulseth HL, Olsen DB, Greve-Isdahl M, Watle SV, Estensen ME, Broch K, Haugaa KH, Hasselberg NE.   +19 more
europepmc   +1 more source

Variability in the TLR3 type I interferon pathway is predictive of RNA vaccine responses. [PDF]

Sci Adv
Ng WW, Sugrue J, Rosa Duque JS, Rouilly V, Bondet V, Albert C, Dubois F, Robert M, Leung D, Chung P, Luk THY, Li ABS, Hung RL, Villain E, Briard M, Yip G, Consortium MI, Larocque D, Patin E, Quintana-Murci L, Leung GM, Ni MY, Goncalves P, Schwartz O, Di Santo J, Bruzzone R, Peiris M, Lau YL, Duffy D.   +28 more
europepmc   +1 more source

Post-booster longitudinal plasma proteomic changes following BNT162b2 COVID-19 vaccination in Qatar. [PDF]

Front Immunol
Bentebbal S, Zaqout A, Meqbel B, Bensmail I, Aldushain A, de la Fuente A, Thomas R, Naik A, Shaath H, Al-Akl NS, Adam A, Moussa HYA, Shin KC, Taha RZ, Abukhattab M, Al-Maslamani MA, Alajez NM, Arredouani A, Park Y, Abdulla SA, El-Agnaf OMA, Abdesselem HB, Omrani AS, Decock J.   +23 more
europepmc   +1 more source

NVX-CoV2372, monovalent mRNA and bivalent mRNA vaccines elicit broadly cross-reactive antibodies against emerging SARS-CoV-2 variants. [PDF]

Hum Vaccin Immunother
Poh XY, Mah SYY, Yeoh AYY, Chavatte JM, Lim DRX, Tan CCY, Tang HL, Gandhi M, Rahman N, Rao S, Chia PY, Sadarangani SP, Chin YQ, Ng LFP, Renia L, Lin RTP, Lye DC, Wang LF, Tan CW, Young BE.   +19 more
europepmc   +1 more source

Cellular Immune Response Induced by mRNA Vaccines Against SARS-CoV-2. [PDF]

Immun Inflamm Dis
Tovar V, Sánchez IP, Rugeles MT, Taborda NA, Hernandez JC.   +4 more
europepmc   +1 more source

Temporal dynamics of SARS-CoV-2 antibodies and IgG subclasses following multiple doses and diverse COVID-19 vaccine combinations. [PDF]

Front Immunol
Meyer J, Hoerauf A, Dubiel AE, Kovačević P, Trudić A, Primorac D, Hübner MP, Adjobimey T, Parcina M.   +8 more
europepmc   +1 more source